We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+11.77%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.63B
AUM Growth
-$1.1B
Cap. Flow
-$769M
Cap. Flow %
-21.2%
Top 10 Hldgs %
50.26%
Holding
130
New
22
Increased
12
Reduced
43
Closed
31

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$43.3M
2
PODD icon
Insulet
PODD
+$22.7M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$21.9M
4
SEPN
Septerna Inc
SEPN
+$17.7M
5
PEN icon
Penumbra
PEN
+$16.7M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$88.3M
2
BHVN icon
Biohaven
BHVN
+$74.2M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$50.4M
4
APGE icon
Apogee Therapeutics
APGE
+$49.4M
5
APLT
Applied Therapeutics
APLT
+$44.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$297M 8.18%
6,392,106
+76,173
+1% +$2.86M
ACLX
2
DELISTED
Arcellx
ACLX
$267M 7.35%
3,478,888
-409,781
-11% -$35.4M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$228M 6.29%
24,245,952
-3,811,504
-14% -$39.6M
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.34B
$206M 5.68%
3,680,473
+120,259
+3% +$6.64M
NUVL
5
DELISTED
Nuvalent
NUVL
$205M 5.65%
2,619,977
-359,258
-12% -$33.5M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$2.02B
$164M 4.51%
22,112,266
-4,505,443
-17% -$41.8M
PCVX icon
7
Vaxcyte
PCVX
$7.65B
$141M 3.88%
1,718,417
-309,191
-15% -$30.7M
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$108M 2.97%
1,288,328
-333,887
-21% -$27.4M
CNTA
9
DELISTED
Centessa Pharmaceuticals
CNTA
$106M 2.93%
6,349,220
+66,930
+1% +$1.11M
PRAX icon
10
Praxis Precision Medicines
PRAX
$8.15B
$102M 2.82%
1,329,735
+165,700
+14% +$12M
AORT icon
11
Artivion
AORT
$1.34B
$79.9M 2.2%
2,793,703
– –
MGTX icon
12
MeiraGTx Holdings
MGTX
$1.07B
$76.6M 2.11%
12,581,103
– –
EWTX icon
13
Edgewise Therapeutics
EWTX
$4.21B
$71.7M 1.98%
2,685,537
+355,243
+15% +$11.3M
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
$67.5M 1.86%
1,501,040
-1,703,936
-53% -$88.3M
IMTX icon
15
Immatics
IMTX
$1.18B
$66.7M 1.84%
9,383,456
+1,297,297
+16% +$11.1M
PODD icon
16
Insulet
PODD
$11.8B
$60.6M 1.67%
232,269
+90,000
+63% +$22.7M
SYRE icon
17
Spyre Therapeutics
SYRE
$8.28B
$59.9M 1.65%
2,574,723
-297,824
-10% -$8.73M
ATXS
18
DELISTED
Astria Therapeutics
ATXS
$58M 1.6%
6,485,420
– –
EOLS icon
19
Evolus
EOLS
$395M
$56.8M 1.57%
5,145,846
-210,776
-4% -$2.96M
AXSM icon
20
Axsome Therapeutics
AXSM
$11.7B
$56.2M 1.55%
664,074
-118,770
-15% -$10.9M
CRGX
21
DELISTED
CARGO Therapeutics
CRGX
$53.1M 1.46%
3,683,004
– –
IMVT icon
22
Immunovant
IMVT
$7.78B
$53M 1.46%
2,139,199
-239,563
-10% -$6.8M
PTGX icon
23
Protagonist Therapeutics
PTGX
$8.68B
$49.1M 1.35%
1,271,662
-102,901
-7% -$4.49M
APGE icon
24
Apogee Therapeutics
APGE
$10.1B
$47.4M 1.31%
1,047,232
-967,775
-48% -$49.4M
ALDX icon
25
Aldeyra Therapeutics
ALDX
$95.3M
$46.3M 1.28%
9,275,851
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Perceptive Advisors held 130 positions worth $3.63B, down 23% from $4.73B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $769M in Q4 2024, closing 31 positions and reducing 43 holdings. Its most notable exit was Biohaven, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Janux Therapeutics worth $43.8M.

  • Perceptive Advisors's largest Q4 2024 buy was Janux Therapeutics: 817,895 shares worth $43.8M.
  • Perceptive Advisors added most to Insulet in Q4 2024, an estimated $22.7M increase.
  • Perceptive Advisors's biggest Q4 2024 reduction was Soleno Therapeutics, cutting an estimated $88.3M.
  • Perceptive Advisors fully exited Biohaven in Q4 2024, selling an estimated $74.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.63B portfolio in Q4 2024.
  • Perceptive Advisors opened 22 new positions and closed 31 in Q4 2024.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $3.63B.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.